UniQure is breathing a sigh of relief after its controversial gene therapy for Huntington’s disease successfully cleared a critical regulatory hurdle. The company has...
Swiss banking giant UBS has downgraded its outlook on the Spanish construction firm Ferrovial, shifting the stock from a buy to neutral following the...